for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

カーディナル・ヘルス・インク

CAH.N

現在値

48.54USD

変化

-0.09(-0.19%)

出来高

881,787

本日のレンジ

48.53

 - 

49.26

52週レンジ

44.93

 - 

62.94

∙ 約20分前の相場を表示しています。

適時開示

Drug Distributors Announce Proposed Opioid Settlement Will Proceed To Next Phase

Sept 4 (Reuters) - Mckesson Corp: :DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT WILL PROCEED TO NEXT PHASE.MCKESSON- UNDER PREVIOUSLY SAID PROPOSED SETTLEMENT DEAL, PROCESS DESIGNED TO RESOLVE OPIOID CLAIMS OF STATE & LOCAL GOVERNMENTAL ENTITIES ENOUGH STATES AGREED TO SETTLE TO PROCEED TO NEXT PHASE.ALL 5 TERRITORIES AND WASHINGTON DC HAD AFFIRMATIVELY SIGNED ON TO AGREEMENT..THIS NEXT PHASE IS NOTICE TO SUBDIVISIONS, AND SUBDIVISION SIGN-ON PERIOD.MCKESSON- IF CONDITIONS ARE SATISFIED, SETTLEMENT WOULD BECOME EFFECTIVE 60 DAYS AFTER DISTRIBUTORS DETERMINE THAT THERE IS SUFFICIENT PARTICIPATION TO PROCEED.FINAL PAYMENT AMOUNT WILL DEPEND ON SEVERAL FACTORS, INCLUDING FINAL PARTICIPATION RATE OF STATES AND POLITICAL SUBDIVISIONS.COMPANIES WILL MAKE THEIR FIRST ANNUAL SETTLEMENT PAYMENT INTO ESCROW ON OR BEFORE SEPTEMBER 30, 2021.PAYMENT WILL BE DISBURSED FOLLOWING EFFECTIVE DATE OR RETURNED TO DISTRIBUTORS IF SETTLEMENT DOES NOT BECOME EFFECTIVE.

NRx Pharmaceuticals To Work With Cardinal Health To Ensure Efficient Distribution Of Potential Therapies

Aug 26 (Reuters) - NRX Pharmaceuticals Inc <NRXP.O>::NRX PHARMACEUTICALS TO WORK WITH CARDINAL HEALTH TO ENSURE EFFICIENT DISTRIBUTION OF POTENTIAL THERAPIES.NRX PHARMACEUTICALS - CARDINAL HEALTH THIRD PARTY LOGISTICS SERVICES TO PROVIDE LOGISTICAL,DISTRIBUTION SUPPORT FOR ZYESAMI UPON POTENTIAL FDA APPROVAL.NRX PHARMACEUTICALS - CARDINAL HEALTH SPECIALTY PHARMACEUTICAL DISTRIBUTION TO SERVE AS EXCLUSIVE DISTRIBUTOR FOR ZYESAMI UPON POTENTIAL FDA APPROVAL.

Cardinal Health Issued Voluntary Medical Device Correction Notice On June 16, 2021 For Argyle Uvc Insertion Tray Containing Safety Scalpel N11

Aug 20 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH - ISSUED VOLUNTARY MEDICAL DEVICE CORRECTION NOTICE ON JUNE 16, 2021 FOR ARGYLE UVC INSERTION TRAY CONTAINING SAFETY SCALPEL N11.CARDINAL HEALTH - CORRECTION NOTICE APPLIES TO ALL UNITS MANUFACTURED BETWEEN AUG 13, 2019 & MARCH 20, 2021.

FDA Says Cardinal Health Recalls Argyle Uvc Insertion Tray Due To Missing Instructions For Use For The Safety Scalpel N11

Aug 20 (Reuters) - Cardinal Health Inc <CAH.N>::FDA SAYS CARDINAL HEALTH RECALLS ARGYLE UVC INSERTION TRAY DUE TO MISSING INSTRUCTIONS FOR USE FOR THE SAFETY SCALPEL N11.FDA SAYS THERE WERE TWO REPORTS OF DEATH IN WHICH THE SAFETY SCALPEL WITHIN THE UVC KIT LOCKED PERMANENTLY AND THE CLINICIAN WAS UNABLE TO UNLOCK.FDA SAYS THERE HAVE BEEN 10 COMPLAINTS REPORTED ABOUT DEVICE ISSUE.FDA SAYS IDENTIFIED ARGYLE UVC INSERTION TRAY AS A CLASS I RECALL.Further company coverage: CAH.N. ((Reuters.Briefs@thomsonreuters.com;)).

Cardinal Health Extends Pharmaceutical Distribution Agreements With CVS Health

Aug 11 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH EXTENDS PHARMACEUTICAL DISTRIBUTION AGREEMENTS WITH CVS HEALTH.CARDINAL HEALTH - EXTENDED AGREEMENTS WITH CVS HEALTH TO DISTRIBUTE PHARMACEUTICALS TO RETAIL PHARMACIES & DISTRIBUTION CENTERS THROUGH JUNE 30, 2027.COMPANY REAFFIRMS ITS FISCAL YEAR 2022 GUIDANCE RANGE FOR NON-GAAP DILUTED EARNINGS PER SHARE ATTRIBUTABLE TO CARDINAL HEALTH.FY2022 EARNINGS PER SHARE VIEW $5.93 -- REFINITIV IBES DATA.

Cardinal Health Posts Q4 Non-Gaap Earnings Per Share $0.77

Aug 5 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH REPORTS FOURTH QUARTER AND FULL YEAR RESULTS FOR FISCAL YEAR 2021.Q4 NON-GAAP EARNINGS PER SHARE $0.77.Q4 GAAP EARNINGS PER SHARE $0.40.Q4 REVENUE $42.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $40.42 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.20 -- REFINITIV IBES DATA.INCREASING ENTERPRISE COST SAVINGS TARGET BY AN ADDITIONAL $250 MILLION TO $750 MILLION BY FISCAL YEAR 2023."DISAPPOINTED WITH OUR Q4 RESULTS".FOURTH-QUARTER REVENUE FOR PHARMACEUTICAL SEGMENT INCREASED 15% TO $38.3 BILLION.CARDINAL HEALTH - GAAP, NON-GAAP OPERATING EARNINGS DURING Q4 AND FY 2021 WERE ADVERSELY IMPACTED BY A $197 MILLION COVID-19-RELATED INVENTORY RESERVE.SEES 2022 NON-GAAP EARNINGS PER SHARE $5.60 - $5.90.SEES 2022 CAPITAL EXPENDITURES $400 MILLION- $450 MILLION.CARDINAL HEALTH - 2022 NON-GAAP EPS GUIDANCE REFLECTS A NET TAILWIND RELATED TO COVID-19 OF ABOUT $200 MILLION VERSUS PRIOR YEAR.CARDINAL HEALTH - Q4 AND FY GAAP DILUTED EPS WERE ALSO NEGATIVELY IMPACTED BY $149 MILLION & $1.17 BILLION PRE-TAX CHARGES RELATED TO OPIOID LAWSUITS.CARDINAL HEALTH QTRLY REVENUE FOR PHARMACEUTICAL SEGMENT DRIVEN BY SALES GROWTH FROM LARGE PHARMACEUTICAL DISTRIBUTION, SPECIALTY SOLUTIONS CUSTOMERS.

AmerisourceBergen, Cardinal Health & McKesson Announce Proposed Opioid Settlement Agreement

July 21 (Reuters) - Amerisourcebergen Corp <ABC.N>::AMERISOURCEBERGEN - COS NEGOTIATED PROPOSED AGREEMENT TO SETTLE A SUBSTANTIAL MAJORITY OF OPIOID LAWSUITS FILED BY STATE & LOCAL GOVERNMENTAL ENTITIES.AMERISOURCEBERGEN - BELIEVE PROPOSED AGREEMENT, SETTLEMENT PROCESS, ARE IMPORTANT STEPS TOWARD ACHIEVING RESOLUTION OF GOVERNMENTAL OPIOID CLAIMS.AMERISOURCEBERGEN CORP - AS PART OF SETTLEMENT, WOULD BE RESPONSIBLE FOR CONTRIBUTIONS OF UP TO $6.4 BILLION, PAYABLE OVER 18 YEARS.AMERISOURCEBERGEN CORP - COMPANIES WILL MAKE THEIR FIRST ANNUAL SETTLEMENT PAYMENT INTO ESCROW ON OR BEFORE SEPTEMBER 30, 2021.AMERISOURCEBERGEN CORP - AS PART OF SETTLEMENT, CARDINAL HEALTH WOULD BE RESPONSIBLE FOR CONTRIBUTIONS OF UP TO $6.4 BILLION, PAYABLE OVER 18 YEARS.AMERISOURCEBERGEN CORP - AS PART OF SETTLEMENT, MCKESSON WOULD BE RESPONSIBLE FOR CONTRIBUTIONS OF UP TO $7.9 BILLION, PAYABLE OVER 18 YEARS.AMERISOURCEBERGEN - IF SETTLEMENT CANNOT BE FINALIZED & PLAINTIFFS PURSUE CLAIMS, COS WILL CONTINUE TO ASSERT LEGAL DEFENSES IN PENDING LITIGATION.

Cardinal Health Nuclear & Precision Health Solutions Receives U.S. Food And Drug Administration Approval For New Lymphoseek Pediatric Indication

June 10 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH™ NUCLEAR & PRECISION HEALTH SOLUTIONS RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR NEW LYMPHOSEEK® PEDIATRIC INDICATION.

Cardinal Health Reports Q3 Revenue $39.3 bln

May 6 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH REPORTS THIRD-QUARTER RESULTS FOR FISCAL YEAR 2021.Q3 NON-GAAP EARNINGS PER SHARE $1.53.Q3 GAAP EARNINGS PER SHARE $0.40.Q3 REVENUE $39.3 BILLION.SEES FY NON-GAAP EARNINGS PER SHARE $5.90 TO $6.05.NARROWED FY21 EARNINGS GUIDANCE.Q3 EARNINGS PER SHARE VIEW $1.55, REVENUE VIEW $40.09 BILLION -- REFINITIV IBES DATA.CARDINAL HEALTH - THIRD-QUARTER REVENUE FOR PHARMACEUTICAL SEGMENT WAS FLAT AT $35.1 BILLION.

Cardinal Health-Launches Outcomes

April 27 (Reuters) - Cardinal Health Inc <CAH.N>::CARDINAL HEALTH-LAUNCHES OUTCOMES, A DIGITAL ECOSYSTEM CONNECTING PHARMACISTS, PAYERS & PHARMA COS TO MITIGATE CHALLENGES OF MEDICATION NON-ADHERENCE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up